Skip to main navigation
Barinthus Biotherapeutics logo
Top Navigation
  • Home
  • About Us
    • Overview
    • Our Team
    • A Name with Purpose
  • Technology
    • Overview
    • Viral Vector Platforms
    • Synthetic Platforms
  • Pipeline
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Partnerships
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Investors
    • Overview
    • News & Filings
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Investor FAQs
    • Contact IR
  • Careers
    • Overview
    • Working Here
    • Diversity & Inclusion
    • Our Values
    • Recruitment Companies
  • Contact
    • Overview
    • Patient Enquiries
Select Page

Quarterly Results

Toolkit
  • Subscribe
  • RSS Feeds
  • Contact IR
  • Presentations
Sub Nav News & Filings
Press Releases
SEC Filings
Annual Reports and AGM
Quarterly Results
Quarterly Results
Show all

Quarterly Results

2023

Q2

  • Q2

Q1

  • Q1

Quarterly Results

2022

Q4

  • Full Year

Q3

  • Q3

Q2

  • Q2

Q1

  • Q1

Quarterly Results

2021

Q4

  • Q4 2021

Q3

  • Q3 2021

Q2

  • Q2 2021

Q1

  • Q1 2021

Barinthus Biotherapeutics plc

Unit 6-10
Zeus Building
Rutherford Avenue
Harwell OX11 0DF
United Kingdom

T: +44 (0)1865 818808

Footer Links
Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact
Barinthus Biotherapeutics logo
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer.
© Barinthus Biotherapeutics 2026 All rights reserved.
Social Media Links
  • Follow us on X
  • Follow us on LinkedIn